RetroLoveMi
The Effect of Lormetazepam Versus Midazolam in Critically Ill Patients on Hospital Mortality: a Retrospective Cohort Trial
Sponsor study identifier
observational
3,314
0 countries
N/A
Study Start
January 1, 2006
Actual (reported)Primary Completion
December 31, 2018
Actual (reported)Study Completion
December 31, 2018
Actual (reported)The aim of this retrospective cohort study is to evaluate the effect of lormetazepam versus midazolam on hospital mortality, intensive care unit outcomes and sedation management. The hypothesis is that patients receiving midazolam have a 5% higher hospital mortality in comparison to patients receiving lormetazepam.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2018
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 1, 2006
Actual (reported)December 31, 2018
Actual (reported)December 31, 2018
Actual (reported)May 22, 2020
Actual (reported)May 29, 2020
Actual (reported)Hospital Mortality
Proportion of patients that between hospital admission and hospital discharge
On average 20 days, for each study subject measured up to study completion day 12-31-2018
Incidence of delirium during the intensive care unit stay
On average 7 days, for each study subject measured up to study completion day 12-31-2018
Duration of delirium during the intensive care unit stay
On average 3 days, for each study subject measured up to study completion day 12-31-2018
Hospital length of stay
On average 30 days, for each study subject measured up to study completion day 12-31-2018
Intensive care unit length of stay
On average 7 days, for each study subject measured up to study completion day 12-31-2018
Duration of mechanical ventilation
On average 4 days, for each study subject measured up to study completion day 12-31-2018
Critically ill intensive care unit patients receiving midazolam
Critically ill intensive care unit patients receiving lormetazepam
In this retrospective analysis we compared critically ill ICU patients receiving midazolam to those receiving lormetazepam.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Intensive care unit patients at the Charité - Universitätsmedizin Berlin that received either midazolam or lormetazepam.
3,314 participants (actual enrollment reported by the registry).
First Submitted
May 22, 2020
First Posted
May 29, 2020
Study Start
January 1, 2006
Actual (reported)Use of In-Line Filtration in Critically Ill Children
Contact the study team to confirm eligibility.
Primary Completion
December 31, 2018
Actual (reported)Study Completion
December 31, 2018
Actual (reported)Last Updated
May 29, 2020
Record last verified: 2020-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: